PURPOSE: High-throughput "-omic" technologies have enabled the detailed analysis of metabolic networks in several cancers, but NETs have not been explored to date. We aim to assess the metabolomic profile of NET patients to understand metabolic deregulation in these tumors and identify novel biomarkers with clinical potential. METHODS: Plasma samples from 77 NETs and 68 controls were profiled by GC-MS, CE-MS and LC-MS untargeted metabolomics. OPLS-DA was performed to evaluate metabolomic differences. Related pathways were explored using Metaboanalyst 4.0. Finally, ROC and OPLS-DA analyses were performed to select metabolites with biomarker potential. RESULTS: We identified 155 differential compounds between NETs and controls. We have detected an increase of bile acids, sugars, oxidized lipids and oxidized products from arachidonic acid and a decrease of carnitine levels in NETs. MPA/MSEA identified 32 enriched metabolic pathways in NETs related with the TCA cycle and amino acid metabolism. Finally, OPLS-DA and ROC analysis revealed 48 metabolites with diagnostic potential. CONCLUSIONS: This study provides, for the first time, a comprehensive metabolic profile of NET patients and identifies a distinctive metabolic signature in plasma of potential clinical use. A reduced set of metabolites of high diagnostic accuracy has been identified. Additionally, new enriched metabolic pathways annotated may open innovative avenues of clinical research.
PURPOSE: High-throughput "-omic" technologies have enabled the detailed analysis of metabolic networks in several cancers, but NETs have not been explored to date. We aim to assess the metabolomic profile of NET patients to understand metabolic deregulation in these tumors and identify novel biomarkers with clinical potential. METHODS: Plasma samples from 77 NETs and 68 controls were profiled by GC-MS, CE-MS and LC-MS untargeted metabolomics. OPLS-DA was performed to evaluate metabolomic differences. Related pathways were explored using Metaboanalyst 4.0. Finally, ROC and OPLS-DA analyses were performed to select metabolites with biomarker potential. RESULTS: We identified 155 differential compounds between NETs and controls. We have detected an increase of bile acids, sugars, oxidized lipids and oxidized products from arachidonic acid and a decrease of carnitine levels in NETs. MPA/MSEA identified 32 enriched metabolic pathways in NETs related with the TCA cycle and amino acid metabolism. Finally, OPLS-DA and ROC analysis revealed 48 metabolites with diagnostic potential. CONCLUSIONS: This study provides, for the first time, a comprehensive metabolic profile of NET patients and identifies a distinctive metabolic signature in plasma of potential clinical use. A reduced set of metabolites of high diagnostic accuracy has been identified. Additionally, new enriched metabolic pathways annotated may open innovative avenues of clinical research.
Authors: A M Larson; S S Hedgire; V Deshpande; A O Stemmer-Rachamimov; M G Harisinghani; C R Ferrone; U Shah; E A Thiele Journal: Clin Genet Date: 2011-11-29 Impact factor: 4.438
Authors: Anna Karpathakis; Harpreet Dibra; Chistodoulos Pipinikas; Andrew Feber; Tiffany Morris; Joshua Francis; Dahmane Oukrif; Dalvinder Mandair; Marinos Pericleous; Mullan Mohmaduvesh; Stefano Serra; Olagunju Ogunbiyi; Marco Novelli; TuVinh Luong; Sylvia L Asa; Matthew Kulke; Christos Toumpanakis; Tim Meyer; Martyn Caplin; Matthew Meyerson; Stephan Beck; Christina Thirlwell Journal: Clin Cancer Res Date: 2015-07-13 Impact factor: 12.531
Authors: Timothy Jewison; Yilu Su; Fatemeh Miri Disfany; Yongjie Liang; Craig Knox; Adam Maciejewski; Jenna Poelzer; Jessica Huynh; You Zhou; David Arndt; Yannick Djoumbou; Yifeng Liu; Lu Deng; An Chi Guo; Beomsoo Han; Allison Pon; Michael Wilson; Shahrzad Rafatnia; Philip Liu; David S Wishart Journal: Nucleic Acids Res Date: 2013-11-06 Impact factor: 16.971
Authors: Amaia Zabala-Letona; Amaia Arruabarrena-Aristorena; Natalia Martín-Martín; Sonia Fernandez-Ruiz; James D Sutherland; Michelle Clasquin; Julen Tomas-Cortazar; Jose Jimenez; Ines Torres; Phong Quang; Pilar Ximenez-Embun; Ruzica Bago; Aitziber Ugalde-Olano; Ana Loizaga-Iriarte; Isabel Lacasa-Viscasillas; Miguel Unda; Verónica Torrano; Diana Cabrera; Sebastiaan M van Liempd; Ylenia Cendon; Elena Castro; Stuart Murray; Ajinkya Revandkar; Andrea Alimonti; Yinan Zhang; Amelia Barnett; Gina Lein; David Pirman; Ana R Cortazar; Leire Arreal; Ludmila Prudkin; Ianire Astobiza; Lorea Valcarcel-Jimenez; Patricia Zuñiga-García; Itziar Fernandez-Dominguez; Marco Piva; Alfredo Caro-Maldonado; Pilar Sánchez-Mosquera; Mireia Castillo-Martín; Violeta Serra; Naiara Beraza; Antonio Gentilella; George Thomas; Mikel Azkargorta; Felix Elortza; Rosa Farràs; David Olmos; Alejo Efeyan; Juan Anguita; Javier Muñoz; Juan M Falcón-Pérez; Rosa Barrio; Teresa Macarulla; Jose M Mato; Maria L Martinez-Chantar; Carlos Cordon-Cardo; Ana M Aransay; Kevin Marks; José Baselga; Josep Tabernero; Paolo Nuciforo; Brendan D Manning; Katya Marjon; Arkaitz Carracedo Journal: Nature Date: 2017-06-28 Impact factor: 49.962
Authors: E González-Flores; R Serrano; I Sevilla; A Viúdez; J Barriuso; M Benavent; J Capdevila; P Jimenez-Fonseca; C López; R Garcia-Carbonero Journal: Clin Transl Oncol Date: 2018-12-07 Impact factor: 3.405
Authors: María Isabel Delgado Dolset; David Obeso; Juan Rodriguez-Coira; Alma Villaseñor; Heleia González Cuervo; Ana Arjona; Coral Barbas; Domingo Barber; Teresa Carrillo; María M Escribese Journal: Front Med (Lausanne) Date: 2022-09-21
Authors: Paweł Komarnicki; Jan Musiałkiewicz; Alicja Stańska; Adam Maciejewski; Paweł Gut; George Mastorakos; Marek Ruchała Journal: J Clin Med Date: 2022-09-21 Impact factor: 4.964